Trial Profile

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanidatamab (Primary) ; Bevacizumab; Capecitabine; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Jazz Pharmaceuticals Inc

12 Sep 2025 Status changed from active, no longer recruiting to completed.
27 Aug 2025 Planned End Date changed from 31 Jul 2025 to 29 Aug 2025.
27 Aug 2025 Planned primary completion date changed from 31 Jul 2025 to 29 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com